Kymera CMO sells 10,508 shares, gets equity grants

Kymera Therapeutics Chief Medical Officer Jared Gollob reported multiple insider transactions.

Rhea-AI Filing Summary

Kymera Therapeutics Chief Medical Officer Jared Gollob reported multiple insider transactions. He sold a net 10,508 shares of common stock in several open-market sales on March 2 and March 4, 2026, at weighted average prices in the mid-$80s per share. On March 2, he also received 17,650 restricted stock units that vest in four equal annual installments after March 2, 2026, and a stock option for 35,300 shares vesting in 48 equal monthly installments, all subject to continued employment. Certain March 2 sales were automatically executed to cover tax withholding from RSU vesting and were not at his discretion.

Insider Trade Summary

Net Seller: 10,508 shares

Net Sell 9 txns

Insider Gollob Jared

Role Chief Medical Officer

Sold 10,508 shs ($917K)

Type	Security	Shares	Price	Value
Sale	Common Stock	492	$83.9965	$41K
Sale	Common Stock	2,519	$85.0364	$214K
Sale	Common Stock	1,437	$85.7807	$123K
Sale	Common Stock	447	$86.6247	$39K
Grant/Award	Stock Option (Right to Buy)	35,300	$0.00	$0.00
Grant/Award	Common Stock	17,650	$0.00	$0.00
Sale	Common Stock	1,510	$87.7509	$133K
Sale	Common Stock	1,055	$88.5004	$93K
Sale	Common Stock	3,048	$89.6574	$273K

Holdings After Transaction: Stock Option (Right to Buy) — 35,300 contracts (Direct); Common Stock — 117,134 shares (Direct)

Footnotes (10)

1. F1. Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date.
2. F2. Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person.
3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.11 to $88.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.11 to $89.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
5. F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.17 to $90.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
6. F6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.36 to $84.3338, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
7. F7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.4475 to $85.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
8. F8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.45 to $86.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
9. F9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.48 to $86.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
10. F10. The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Kymera Therapeutics (KYMR) report for Jared Gollob?

Jared Gollob reported both equity awards and share sales. He received restricted stock units and stock options on March 2, 2026, and sold a total of 10,508 Kymera Therapeutics common shares in multiple open-market transactions on March 2 and March 4, 2026.

How many Kymera Therapeutics (KYMR) shares did Jared Gollob sell and at what prices?

He sold 10,508 common shares in several open-market trades. Reported weighted average sale prices ranged roughly from the low $80s to high $80s per share, with detailed price ranges for each transaction disclosed in accompanying footnotes.

What equity awards did Jared Gollob receive from Kymera Therapeutics (KYMR)?

He received 17,650 restricted stock units and a stock option covering 35,300 shares. The RSUs vest in four equal annual installments after March 2, 2026, while the stock option vests in 48 equal monthly installments, contingent on his continued employment.

How do Jared Gollob’s RSUs at Kymera Therapeutics (KYMR) vest over time?

The 17,650 restricted stock units vest in four equal annual installments. Vesting begins after March 2, 2026, and each installment requires Jared Gollob to remain employed through the applicable vesting date to receive the underlying common shares.

Were all of Jared Gollob’s Kymera Therapeutics (KYMR) share sales discretionary?

Not all of the reported share sales were discretionary. A portion of the March 2, 2026 transactions represented shares sold automatically to cover tax withholding obligations arising from RSU vesting, as disclosed in the footnotes to the insider report.

What are the vesting terms for Jared Gollob’s Kymera Therapeutics (KYMR) stock option grant?

The stock option for 35,300 shares vests in 48 equal monthly installments. Vesting starts after March 2, 2026, and each monthly installment requires Jared Gollob to continue his employment with Kymera Therapeutics through the relevant vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/04/2026 - 06:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gollob Jared

(Last) (First) (Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, 4TH FLOOR

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		A		17,650(1)	A	$0	127,642	D
Common Stock	03/02/2026		S(2)		1,510	D	$87.7509(3)	126,132	D
Common Stock	03/02/2026		S(2)		1,055	D	$88.5004(4)	125,077	D
Common Stock	03/02/2026		S(2)		3,048	D	$89.6574(5)	122,029	D
Common Stock	03/04/2026		S(2)		492	D	$83.9965(6)	121,537	D
Common Stock	03/04/2026		S(2)		2,519	D	$85.0364(7)	119,018	D
Common Stock	03/04/2026		S(2)		1,437	D	$85.7807(8)	117,581	D
Common Stock	03/04/2026		S(2)		447	D	$86.6247(9)	117,134	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$90.1	03/02/2026		A		35,300		(10)	03/01/2036	Common Stock	35,300	$0	35,300	D

Explanation of Responses:

1. Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date.

2. Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.11 to $88.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.11 to $89.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.17 to $90.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.36 to $84.3338, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.4475 to $85.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.45 to $86.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.48 to $86.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

10. The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date.

	/s/ Bruce Jacobs, as Attorney-in-Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.